#United States #Cambridge #MetaVia #Vanoglipel #AI-Modeling

MetaVia's Latest Collaboration Yields Positive Results in AI-Modeling for Vanoglipel

In a significant announcement made by MetaVia Inc. (Nasdaq: MTVA), the biotechnology firm revealed the latest results from its ongoing collaboration with Syntekabio, Inc., a company specializing in AI-driven drug discovery. Utilizing the innovative DeepMatcher® platform, which leverages artificial intelligence to model compound-protein interactions, Syntekabio has successfully identified crucial disease targets for vanoglipel (DA-1241), an oral G-protein-coupled receptor 119 (GPR119) agonist that MetaVia seeks to develop for various cardiometabolic conditions.

The AI analysis pinpointed several key areas of interest, predominantly inflammatory diseases, cardiometabolic disorders, and cancer, all of which align seamlessly with MetaVia's therapeutic goals. Particularly noteworthy was the identification of cancer targets, attributed in part to the reduction in inflammation observed in the AI-predicted pathways. Hyung Heon Kim, the President and CEO of MetaVia, expressed enthusiasm regarding the results, stating, "The AI modeling results provide strong confirmation that vanoglipel engages key inflammatory targets, supporting our strategy in metabolic dysfunction-associated steatohepatitis (MASH) and potential type 2 diabetes (T2D)."

A Closer Look at Vanoglipel

Vanoglipel is not just another compound; it represents a novel approach in treating diseases linked to metabolic dysfunctions. By agonizing GPR119 in the gut, this innovative drug facilitates the release of vital gut peptides like GLP-1, GIP, and PYY which are instrumental in enhancing glucose metabolism, lipid metabolism, and promoting weight loss. Preclinical studies have indicated that vanoglipel has significant positive effects on glucose control, liver inflammation, and overall lipid profiles.

MetaVia's confidence in vanoglipel's therapeutic potential is reinforced by the Phase 2a clinical study, which observed improved hepatic activity and glucose metabolism in 109 patients over a 16-week period. The results were promising, showing a favorable safety and tolerability profile alongside noticeable benefits in metabolic management. Kim noted, "These insights strengthen our belief that we are focusing on the right areas, and we are excited to advance DA-1241 for MASH and T2D."

Continuing the Collaboration with Syntekabio

Looking ahead, MetaVia plans to continue its collaboration with Syntekabio, leveraging their AI platform to explore even more potential indications for vanoglipel and to further refine its therapeutic profile. Given the rapidly evolving landscape of drug discovery, the synergies created through such partnerships place MetaVia in a unique position to potentially lead in the treatment of cardiometabolic diseases.

About Syntekabio

Founded in 2009, Syntekabio Co., Ltd. intertwines biology and AI/ML, advancing drug discovery efficiently. Their platform facilitates the rapid identification of first-in-class compounds and features a supercomputer that supports large-scale drug development initiatives. Their bespoke services allow for optimized drug candidate generation across various disease targets.

Conclusion

With these positive results emerging from its collaboration with Syntekabio, MetaVia is poised to make significant strides in the treatment of cardiometabolic diseases through innovative therapeutic strategies involving AI. These advancements not only underline the company's commitment to addressing significant health challenges but also signal a new era of drug development fueled by cutting-edge technology. The excitement surrounding vanoglipel continues to grow as MetaVia targets its next steps in clinical trials and further explorations into potential disease applications.